BridgeBio Pharma

BridgeBio Pharma’s acoramidis (Attruby®/BEYONTTRA®) shows rapid efficacy in treating transthyretin amyloid cardiomyopathy (ATTR-CM). The ATTRibute-CM study revealed a 49% reduction in cardiovascular mortality or recurrent hospitalizations by Month 30. Extended follow-up showed a 45% reduction in cardiovascular mortality at Month 42 compared to placebo switch. Acoramidis, an oral TTR stabilizer, is approved in the US, Europe, Japan, and the UK, demonstrating near-complete TTR stabilization. It also mitigates rises in NT-proBNP levels.

BridgeBio Pharma’s acoramidis demonstrated a 44% reduction in cardiovascular mortality risk in ATTR-CM patients after 42 months in the ATTRibute-CM open label extension study. The study also showed a 46% hazard reduction in cardiovascular mortality or first cardiovascular hospitalization. Approximately 50% of participants exhibited disease stabilization compared to less than 20% on placebo at month 30. Acoramidis, marketed as Attruby® and BEYONTTRA®, exhibited the fastest benefit observed in a Phase 3 ATTR-CM study, with positive changes seen in 3 months.